---
layout: default
title: Thalidomide
parent: 僅模型預測 (L5)
nav_order: 668
evidence_level: L5
indication_count: 10
---

# Thalidomide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using no additional skill — this is a direct content-generation task per the fully-specified report template already in context; I'll follow it as written using `predicted_indications[0]` (ganglioneuroblastoma).

Note: `predicted_indications[0]` (ganglioneuroblastoma) is the top-ranked candidate purely by TxGNN score, but it has zero supporting trials/literature (L5/Hold). Several lower-ranked candidates (e.g. myeloid leukemia, indolent plasma cell myeloma — both L2/Proceed with Guardrails) have far stronger evidence. I've generated the report strictly on index [0] per the spec; flag if you actually want the report built around one of the better-evidenced candidates instead.

---

# Thalidomide: From Multiple Myeloma to Ganglioneuroblastoma

## One-Sentence Summary

> Thalidomide is a well-known immunomodulatory agent, most recently established (globally) for the treatment of multiple myeloma and erythema nodosum leprosum.
> The TxGNN model predicts it may be effective for **Ganglioneuroblastoma**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure model prediction with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in evidence pack (thalidomide is historically indicated overseas for multiple myeloma and erythema nodosum leprosum; Australian TGA/ARTG registration data unavailable — see Australia Market Information below) |
| Predicted New Indication | Ganglioneuroblastoma |
| TxGNN Prediction Score | 98.96% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for thalidomide in this evidence pack. Thalidomide is broadly recognised as an immunomodulatory and anti-angiogenic agent (acting via cereblon-mediated protein degradation), with established use in multiple myeloma and erythema nodosum leprosum.

The TxGNN model's rationale for this specific prediction states: *"TxGNN assigns a high prediction score, but there is no clinical trial or literature evidence supporting this indication. The anti-angiogenic mechanism is theoretically plausible for neural-crest-derived tumours, but this remains a purely computational prediction without any supporting evidence."*

Ganglioneuroblastoma is a neural-crest-derived tumour, and anti-angiogenic mechanisms have shown some relevance in related tumour types (e.g. neuroblastoma — see the related, better-evidenced candidate in this evidence pack). However, for ganglioneuroblastoma specifically, this link is theoretical only and has not been tested in any trial or study identified to date.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Australia Market Information

Thalidomide currently holds no ARTG entries in Australia (market status: Not Marketed). No product licence data is available in this evidence pack.

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction rests solely on TxGNN's knowledge-graph embedding similarity — there is no clinical trial, case report, or preclinical study directly linking thalidomide to ganglioneuroblastoma. Combined with the absence of TGA/ARTG registration in Australia and missing drug-level safety data (MOA, warnings, contraindications), the evidence base does not support progression beyond hypothesis generation.

**To proceed, the following is needed:**
- Mechanism of action data from DrugBank (currently flagged as a High-severity data gap, DG002)
- TFDA/TGA-equivalent product information — warnings, contraindications, and DDI data (currently flagged as a Blocking data gap, DG001, required before any S1 safety review)
- At least preclinical or case-level evidence specifically linking thalidomide to ganglioneuroblastoma or closely related neural-crest tumours
- Consideration of reprioritising review toward better-evidenced candidates in this same evidence pack (myeloid leukemia and indolent plasma cell myeloma are both rated L2 / Proceed with Guardrails, with multiple completed Phase 2 trials and direct literature support)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

